q&more
My watch list
my.chemie.de  
Login  

News

Construction kit for custom-designed products

Biotechnologists develop robust and efficient methods for the production of new peptide drugs

Jürgen Lecher, Goethe-Universität

From left to right: Dr. Yan-Ni Shi, Prof. Helge Bode, Janik Kranz, Peter Grün und Andreas Tietze.

13-Jun-2019: Microorganisms often assemble natural products similar to product assembly lines. Certain enzymes, non-ribosomal peptide synthetases (NRPS), play a key role in this process. Biotechnologists at Goethe University have now succeeded in changing these enzymes so that entirely new natural products, or even libraries of natural products, can be produced by microorganisms.

Many important natural products such as antibiotics, immunosuppressants, or anti-cancer drugs are produced by microorganisms. These natural products are often small peptides, which in several cases are too complex for a chemical synthesis in the laboratory. In the microbial producers of these drugs, the drugs are generated with the help of the NRPS enzymes in a manner similar to a modern automobile factory: at each station, additional parts are added to the basic structure until finally a complete automobile leaves the factory. In the case of NRPS, a specific amino acid is incorporated and processed at each station (module) so that in the end, peptides emerge that can be linear, cyclic or otherwise modified, and which can also carry unusual amino acids.

Although the basic principles of NRPS have been known for a long time, it was previously hardly possible to modify these enzymes in an easy and efficient way that also allows the complete assembly of fully artificial enzymes leading to new-to-nature peptides. While in the past NRPS modification usually led to a dramatic drop in the production titre of the desired modified peptides, the Molecular Biotechnology research group of Professor Helge Bode already published a new method in 2018 that avoided this drawback. The group has now further optimized this method allowing the easy production of new peptides in excellent yield.

“We use fragments of natural NRPS systems from different bacteria as building blocks that we connect to each other using specific assembly points we have identified,” Andreas Tietze and Janik Kranz explain the research approach they developed as part of a larger team in the Bode group. “The yields are comparable to the natural production of the non-modified natural products and the new methods also enable the simple production of peptide libraries, which was not possible before”.

The method is so well established, beginners can use it to produce new peptides after a short training period. But to get to this point was a long way. “Following the first promising experiments by Kenan, my PhD student at the time, we worked for a long time on the project with a major part of my group until we were certain that our method fulfilled the requirements of a robust and easily reproducible engineering method,” Bode states. “Thanks to the LOEWE priority programmes MegaSyn and Translational Biodiversity Genomics, we had the necessary personnel and financial support, and could concentrate completely on the project.”

The next step is to modify the first clinically relevant drugs with this method and produce them in microorganisms applying biotechnology methods. The conditions for this are good - Bode was only recently awarded one of the renowned ERC Advanced Grants from the European Research Council in order to further optimize the methods over the next five years.

Original publication:
Kenan A. J. Bozhüyük, Annabell Linck, Andreas Tietze, Janik Kranz, Frank Wesche, Sarah Nowak, Florian Fleischhacker, Yan-Ni Shi, Peter Grün, Helge B. Bode; "Modification and de novo design of non-ribosomal peptide synthetases (NRPS) using specific assembly points within condensation domains"; Nature Chemistry; 2019

Facts, background information, dossiers

  • peptide drugs
  • enzymes

More about Uni Frankfurt am Main

  • News

    Possible Achilles’ heel of SARS-CoV-2 virus identified

    When the SARS-CoV-2 virus penetrates human cells, it lets the human host cell produce proteins for it. One of these viral proteins, called PLpro, is essential for the replication and rapid spread of the virus. An international team of researchers led by Goethe University and University Hosp ... more

    How particulate matter arises from pollutant gases

    When winter smog takes over Asian mega-cities, more particulate matter is measured in the streets than expected. An international team, including researchers from Goethe University Frankfurt, as well as the universities in Vienna and Innsbruck, has now discovered that nitric acid and ammoni ... more

    Pool testing of SARS-CoV-02 samples increases worldwide test capacities many times over

    Researchers at the German Red Cross Blood Donor Service in Frankfurt headed by Professor Erhard Seifried, and the Institute for Medical Virology at the University Hospital Frankfurt at Goethe University headed by Professor Sandra Ciesek succeeded in developing a procedure that makes it poss ... more

  • q&more articles

    From feast to famine and back – no problem for bacteria

    Bacteria are true survivors. In the course of evolution, they have developed numerous strategies to adapt to rapidly changing, uncertain environmental conditions. Their metabolism is much more sophisticated than that of human beings. Within minutes they can regulate their gene expression an ... more

    Why biosimilars and not biogenerics?

    Medicines produced using genetic techniques have existed since 2006, called “similar biological medicinal products” or “biosimilars”. Until a year ago, this was a fairly low-profile group, even in expert circles. This has all changed now, however, with the recent licensing of the first bios ... more

    Paradigm shift

    What would medicine be without drugs? But are these drugs being used optimally today? Not at all, as we now know thanks to the findings of molecular medicine. Because for the use of these drugs, it is important to observe two aspects: the disease and the patient. Only slowly is it becom ... more

  • Authors

    Prof. Dr. Jörg Soppa

    Jörg Soppa, born in 1958, studied biochemistry in Tübingen and then went on to do his doctorate at the Max Planck Institute of Biochemistry in Martinsried near Munich. In 1990 he established his own research group there and held courses at the Institute of Genetics and Microbiology of Munic ... more

    Prof. Dr. Heinfried H. Radeke

    Heinfried H. Radeke studied medicine at the Hannover Medical School (MHH) and received his medical license in 1985. His Ph.D. thesis was recognized as the best research dissertation of 1986. After two years as an assistant physician at the Göttingen University Hospital, he began his career ... more

    Prof. Dr. Theo Dingermann

    Theodor Dingermann, born 1948, studied pharmacy in Erlangen ­and received his doctor title in 1980 to become Dr. rer. nat. In 1990 he was offered the C4 professorship at the Institute for Pharmaceutical Biology, University of Frankfurt.  From 2000 to 2004 he was President of the German Phar ... more

q&more – the networking platform for quality excellence in lab and process

The q&more concept is to increase the visibility of recent research and innovative solutions, and support the exchange of knowledge. In the broad spectrum of subjects covered, the focus is on achieving maximum quality in highly innovative sectors. As a modern knowledge platform, q&more offers market participants one-of-a-kind networking opportunities. Cutting-edge research is presented by authors of international repute. Attractively presented in a high-quality context, and published in German and English, the original articles introduce new concepts and highlight unconventional solution strategies.

> more about q&more

q&more is supported by:

 

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE